Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial results ...

Inovio Pharmaceuticals (NASDAQ:INO – Free Report) had its target price lowered by Royal Bank of Canada from $6.00 to $5.00 in a research report sent to investors on Wednesday,Benzinga reports. The ...

Shares of Inovio Pharmaceuticals stock opened at $1.92 on Friday. The firm has a market cap of $50.11 million, a price-to-earnings ratio of -0.91 and a beta of 0.92. The business has a 50-day ...

Shares of Inovio Pharmaceuticals Inc. INO shed 1.03% to $1.92 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index COMP rising 0.52% ...

RBC Capital lowered the firm’s price target on Inovio (INO) to $5 from $6 and keeps a Sector Perform rating on the shares. The company ...

In a report released yesterday, Gregory Renza from RBC Capital maintained a Hold rating on Inovio Pharmaceuticals (INO – Research Report), with ...

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and ...

Shares of Inovio Pharmaceuticals Inc. INO shed 1.02% to $1.94 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.33% ...

As U.S. stocks sink on tariff fears, the E.U. and China stand out.